Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US
There is little evidence to support biologics having longer periods of market exclusivity or protection from negotiation. As a result of differential treatment, US law appears to overly reward the development of biologics relative to small-molecule drugs.
Authors
- Matthew Vogel (ORCID: https://orcid.org/0009-0005-5216-444X)
- S. Sean Tu (ORCID: https://orcid.org/0000-0003-0391-8186)
- William B. Feldman (ORCID: https://orcid.org/0000-0003-3467-5869)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Olivier J. Wouters (ORCID: https://orcid.org/0000-0002-2514-476X)
- Reed F. Beall (ORCID: https://orcid.org/0000-0001-8188-7616)
Institutions
- West Virginia University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Calgary (CA)
- John F. Kennedy University (US)
- London School of Economics and Political Science (GB)
Publication Details
- Journal
- JAMA
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1001/jama.2024.16911
- Citations
- 17
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 19.20
Funders
- Arnold Ventures